

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.


1. (Currently Amended) An oral dosage form of a pharmaceutically acceptable base addition salt of a boronic acid of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)₂, ~~compound selected from boronic acids which have a neutral thrombin P1 domain linked to a hydrophobic moiety capable of binding to the thrombin S2 and S3 subsites, and salts, prodrugs and prodrug salts of such acids,~~ the dosage form comprising a solid phase formulation comprising the compound and being adapted for reconstitution of the formulation to form a liquid preparation.

2. – 9. (Canceled)

10. (Currently amended) An oral pharmaceutical dosage form adapted to be reconstituted either prior to administration into a liquid for oral administration, or in the mouth, and said oral pharmaceutical dosage form comprising a pharmaceutically acceptable base addition salt of a boronic acid of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)₂

~~a compound selected from boronic acids of formula (III) and salts, prodrugs and prodrug salts thereof;~~

~~where:~~



(III)

~~X is H (to form NH₂) or an amino-protecting group;~~

~~aa¹ is an amino acid having a hydrocarbyl side chain containing no more than 20 carbon atoms and comprising at least one cyclic group having up to 13 carbon atoms;~~

~~aa² is an imino acid having from 4 to 6 ring members; and~~

~~R¹ is a group of the formula (CH₂)_s Z, where s is 2, 3 or 4 and Z is OH, OMe, OEt or halogen, wherein halogen is F, Cl, Br or I.~~

11. – 16. (Canceled)

17. (Currently amended) The oral dosage form of claim 1, 9 wherein the salt comprises a salt of the boronic acid with a metal.

18. (Currently amended) The oral dosage form of claim 17, wherein the metal comprises an alkali metal.

19. (Currently amended) The oral dosage form of claim 1 which comprises boronate ions derived from the boronic acid and has a stoichiometry consistent with the boronate ions carrying a single negative charge.

20. (Currently amended) The oral dosage form of claim 1 which comprises:
a pharmaceutical formulation which contains said pharmaceutically acceptable base addition salt compound and is in the form of powder or granules; and
a sealed container in which the formulation is contained and from which the formulation is to be dispensed for reconstitution.

21. (Canceled)

22. (Canceled)

23. (Currently amended) The oral dosage form of claim 20, wherein the container is a sachet.

24. (Currently amended) The oral dosage form of claim 1 wherein the solid phase formulation is a pharmaceutical formulation in the form of an effervescent tablet which contains an effervescent system, or is a fast melt pharmaceutical formulation.

25. (Canceled)

26. (Currently amended) The oral dosage form of claim 20 which comprises from about 0.2 to about 1.5 mol of said pharmaceutically acceptable base addition salt ~~the compound~~, calculated on the basis of the boronic acid.

27. (Canceled)

28. (Currently amended) The oral dosage form of claim 1 which is adapted to be reconstituted to form a solution having a volume of from about 50_ml to about 150_ml.

29. (Original) A pharmaceutical formulation comprising a pharmaceutically acceptable base addition salt of the acid Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)₂, the formulation being in the form of a powder or granules in a sachet or of an effervescent tablet.

30. – 51. (Canceled)

52. (Currently Amended) An aqueous solution comprising a pharmaceutically acceptable base addition salt of a boronic acid of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)₂, ~~which has a neutral thrombin P1 domain linked to a hydrophobic moiety capable of binding to the thrombin S2 and S3 subsites~~, the solution having a pH of about 9 or more.

53. (Currently Amended) The aqueous solution of claim 52, wherein the pH is about 9 to about 9.5.

54. (Currently Amended) An aqueous solution comprising a pharmaceutically acceptable base addition salt of a boronic acid of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)₂ ~~which has a neutral thrombin P1 domain linked to a hydrophobic moiety capable of binding to the thrombin S2 and S3 subsites~~ and a pharmaceutically acceptable organic acid, the solution having a pH of from about 4 to about 8.